Treatment of Ventilator-Associated Pneumonia with Risk Factors for Antimicrobial Resistance
In mechanically ventilated patients who develop pneumonia, the presence of any one risk factor for antimicrobial resistance substantially changes the empiric antibiotic strategy. These clinical features increase the probability of resistant pathogens — including MRSA and multidrug-resistant gram-negative organisms — and must be identified before treatment is initiated.
Risk Factors for Antimicrobial Resistance
- Prior intravenous antibiotic use within 90 days
- Septic shock at the time of VAP
- Acute respiratory distress syndrome (ARDS) preceding VAP
- Five or more days of hospitalization prior to the occurrence of VAP
- Acute renal replacement therapy prior to VAP onset
Empiric Treatment Approach
When one or more of the above risk factors is present, empiric intravenous therapy is broadened to include an agent active against MRSA alongside dual antipseudomonal coverage from two different antibiotic classes, given as a short defined course. Agent selection within each category and the complete regimen are detailed in the structured protocol.
References
DOI: 10.1093/cid/ciw353
- We suggest including an agent active against MRSA for the empiric treatment of suspected VAP only in patients with any of the following: a risk factor for antimicrobial resistance (Table 2), patients being treated in units where >10%–20% of S. aureus isolates are methicillin resistant, and patients in units where the prevalence of MRSA is not known (weak recommendation, very low-quality evidence).
- In patients with suspected VAP, we recommend including coverage for S. aureus, P. aeruginosa, and other gram-negative bacilli in all empiric regimens (strong recommendation, low-quality evidence).
- We suggest prescribing 2 antipseudomonal antibiotics from different classes for the empiric treatment of suspected VAP only in patients with any of the following: a risk factor for antimicrobial resistance (Table 2), patients in units where >10% of gram-negative isolates are resistant to an agent being considered for monotherapy, and patients in an ICU where local antimicrobial susceptibility rates are not available (weak recommendation, low-quality evidence).
- For patients with VAP, we recommend a 7-day course of antimicrobial therapy rather than a longer duration (strong recommendation, moderate-quality evidence).
View source ↗